search

InMed Pharmaceuticals Inc (INM)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Nasdaq gives InMed 45 days to submit a compliance plan
Sep 19, 2026

Nasdaq gives InMed 45 days to submit a compliance plan

InMed Pharmaceuticals (INM) received a Nasdaq notice due to its shareholders' equity falling below the required minimum for continued listing. The company attributes this to expenses related to its planned merger with Mentari Therapeutics and expects the merger's closing and Mentari's pre-closing financing to restore compliance. InMed has 45 days to submit a compliance plan, with a potential extension of up to 180 days.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral